CA3224861A1 - Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function - Google Patents

Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function Download PDF

Info

Publication number
CA3224861A1
CA3224861A1 CA3224861A CA3224861A CA3224861A1 CA 3224861 A1 CA3224861 A1 CA 3224861A1 CA 3224861 A CA3224861 A CA 3224861A CA 3224861 A CA3224861 A CA 3224861A CA 3224861 A1 CA3224861 A1 CA 3224861A1
Authority
CA
Canada
Prior art keywords
atp
composition
administered
person
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3224861A
Other languages
English (en)
French (fr)
Inventor
John Rathmacher
Larry KOLB
Shawn Baier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsi Usa LLC
Original Assignee
Tsi Usa LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsi Usa LLC filed Critical Tsi Usa LLC
Publication of CA3224861A1 publication Critical patent/CA3224861A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3224861A 2021-06-22 2022-06-22 Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function Pending CA3224861A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213378P 2021-06-22 2021-06-22
US63/213,378 2021-06-22
PCT/US2022/034510 WO2022271813A1 (en) 2021-06-22 2022-06-22 Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function

Publications (1)

Publication Number Publication Date
CA3224861A1 true CA3224861A1 (en) 2022-12-29

Family

ID=84544774

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3224861A Pending CA3224861A1 (en) 2021-06-22 2022-06-22 Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function

Country Status (12)

Country Link
US (1) US20240299435A1 (cg-RX-API-DMAC10.html)
EP (1) EP4358972A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024524288A (cg-RX-API-DMAC10.html)
CN (1) CN117835985A (cg-RX-API-DMAC10.html)
AU (1) AU2022297444A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224861A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003882A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024000517A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP24004256A (cg-RX-API-DMAC10.html)
MX (1) MX2024000145A (cg-RX-API-DMAC10.html)
PE (1) PE20241617A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022271813A1 (cg-RX-API-DMAC10.html)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095695A (ja) * 1998-07-23 2000-04-04 Nippon Koutai Kenkyusho:Kk 精神分裂病治療薬
US20030069203A1 (en) * 2001-06-04 2003-04-10 Lee Steve S. Method for increasing human performance by reducing muscle fatigue and recovery time through oral administration of adenosine triphosphate
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
US20050261239A1 (en) * 2004-05-23 2005-11-24 Universiteit Van Maastricht Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue
KR101424833B1 (ko) * 2006-06-27 2014-08-01 코와 가부시키가이샤 피로 예방 및/또는 회복을 위한 의약
US9522161B2 (en) * 2010-10-26 2016-12-20 Advanced Bio Development, Inc. Performance enhancing composition and method of delivering nutrients
CN113142581B (zh) * 2010-12-23 2025-07-22 阿马曾提斯公司 用于改善线粒体功能的组合物和方法
US20140044690A1 (en) * 2012-08-08 2014-02-13 University Of South Florida High-Energy Compounds for Use in Alzheimer's and Other Neurodegenerative Diseases
BR112015005199B1 (pt) * 2012-09-10 2022-09-06 Metabolic Technologies, Inc Composição, e, método para fornecer um benefício a um animal em necessidade do mesmo
WO2014106860A2 (en) * 2013-01-03 2014-07-10 Laila Nutraceuticals Synergistic dietary supplement compositions for enhancing physical performance and energy levels
US10888576B2 (en) * 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
WO2021046357A1 (en) * 2019-09-05 2021-03-11 Jiangyin Tsi Pharmaceutical Co., Ltd. Compositions containing adenosine triphosphate (atp) and methods of use

Also Published As

Publication number Publication date
PE20241617A1 (es) 2024-08-07
CN117835985A (zh) 2024-04-05
CO2024000517A2 (es) 2024-05-10
AU2022297444A1 (en) 2024-01-18
US20240299435A1 (en) 2024-09-12
EP4358972A4 (en) 2025-04-16
ECSP24004256A (es) 2024-02-29
EP4358972A1 (en) 2024-05-01
WO2022271813A1 (en) 2022-12-29
CL2023003882A1 (es) 2024-07-05
MX2024000145A (es) 2024-03-22
JP2024524288A (ja) 2024-07-05

Similar Documents

Publication Publication Date Title
Rimer et al. Increase in maximal cycling power with acute dietary nitrate supplementation
Kraemer et al. Effects of amino acids supplement on physiological adaptations to resistance training
US20160303177A1 (en) Nutritional supplement
US7629329B2 (en) Method for increasing muscle mass and strength through administration of adenosine triphosphate
Curtis et al. The effects of a pre-workout supplement on measures of alertness, mood, and lower-extremity power
WO2018157258A1 (en) Multi-nutrient composition
US20240299435A1 (en) Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function
Hara et al. Effects of pycnogenol-containing supplement on professional cycling performance: a single-group pretest-posttest pilot study
Allman et al. The Effect of Short Term Beta Alanine Supplementation on Physical Performance and Quality of Life in Parkinson's Disease: A Pilot Study.
Tatlici et al. The effects of beetroot juice supplementation on balance performance of wrestlers
Wax et al. Acute ingestion of L-arginine alpha-ketoglutarate fails to improve muscular strength and endurance in ROTC cadets
Zaheri et al. The effect of ginseng supplement on heart rate, systolic and diastolic blood pressure to resistance training in trained males
Pereira et al. Consumption of energy drinks on cardiovascular and metabolic response and performance. Is there an effect
US20080108698A1 (en) Nutrient Supplement and Use of the Same
RU2848641C1 (ru) Способ повышения общей физической работоспособности спортсменов, специализирующихся в игровых видах спорта
Gouttebarge et al. Short-term oral creatine supplementation in professional football players: a randomized placebo-controlled trial
O’Mathúna Creatine to enhance sports performance
Sakong Effect of beetroot juice supplementation on aerobic and anaerobic capacities, and isokinetic muscle functions in power athletes: 비트 주스 섭취가 파워종목 선수의 유· 무산소성 경기력 요인 및 등속성 근기능에 미치는 영향
Deota Nutritional Status Assessment of Elite Cricketers From Urban Vadodara and Impact Evaluation of a Cocoa Flavanol Rich Drink on the Muscle Recovery
Ali An investigation was conducted using a double-blind, randomized clinical trial to evaluate the effects of L-arginine supplementation on body composition and performance in athletes
Sadeghi et al. Short-term effects of glutamine supplementation on levels of blood lactate and fatigue index in male elite swimmers
Vacher-Weiss The Effects of Beetroot Juice Consumption on Maximal Oxygen Consumption
Sunderland Effect of chronic L-arginine supplementation on oxygen uptake and ventilatory threshold in trained cyclists
Konstantaki et al. The Effect of Caffeine Supplementation on Endurance Performance in Multi Sprint Sports
Stewart How Does Caffeine Supplementation Affect Muscular Performance in Adolescent Males?

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250613

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250613

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260603

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260609

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260618

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260618